Careers  |  Sign In  |  Register

Latest in Oncology

Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
For diagnosis 1 year after sample collection, the test detected mutations in 90% of patients.
The recurrence rate for cystectomy was 38% compared to 59% for TMT.